Navigation Links
Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions
Date:6/28/2011

TCA 650 therapy in the phase 2 trial was administered for the 90-day treatment period with a single insertion of ITCA 650 on day 1 and removal on or about day 90. The extension phase of the 2 trial evaluated higher doses of ITCA 650 using a single device to deliver 3 months of treatment. The phase 3 study planned for 2011 will evaluate treatment regimens involving initial 12-week ITCA 650 dosing at 20 mcg/day transitioning to 60 mcg/day thereafter using ITCA 650 devices of both 6- and 12-month duration.

A downloadable version of the ITCA 650 phase 2 presentation from ADA is available on the Intarcia corporate website at: http://www.intarcia.com/media_presentations.html

About ITCA 650ITCA 650 therapy for type 2 diabetes consists of DUROS continuous subcutaneous delivery of exenatide. Intarcia's delivery technology comprises the DUROS device, a matchstick-size, miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy, and proprietary formulation technology that maintains stability of therapeutic proteins and peptides at human body temperature for extended periods of time.

A single DUROS device can deliver up to a full year of ITCA 650 therapy. Unlike other extended delivery technologies, such as polymers or albumin fusions, DUROS delivery allows for steady state drug delivery upon insertion and near immediate withdrawal of therapy, if required. ITCA 650 is an investigational new drug and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, has been approved in the U.S., Europe and many other markets and is currently marketed as a twice-daily self-injection therapy for type 2 diabetes.

About Type 2 DiabetesAccording to the National Institutes of Health (NIH), "Approximately 23.6 million Americans have type 2 diabetes, which represents 7.8 percent of the U.S. population and about 1/4 o
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference
2. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
3. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
4. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
5. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
6. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
7. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
8. SVS 2011: Ziehm Imaging Presents Latest Mobile C-armTechnology for Intraoperative use
9. Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinsons Disease at International Neuromodulation Society 10th World Congress
10. Tolerx Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
11. TGen and PBS-Bio presents 2 abstracts at AACR conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... May 27, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering and developing innovative therapies primarily in the ... on the status of the Company,s Series A ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... 21 shares of Series A Preferred Stock and ...
(Date:5/27/2015)... Caris Life Sciences®, a leading biotechnology company ... announced it has appointed the Levine Cancer Institute, part ... in the Caris Centers of Excellence for Precision Medicine ... one of the largest cancer care providers throughout the ... annually. Derek Raghavan , M.D., Ph.D., President of ...
(Date:5/26/2015)... Miami (PRWEB) May 26, 2015 ... a new stem cells clinic in Buenos Aires, Argentina. ... a renowned critical care specialist. Pastrana has assembled a ... endocrinology and orthopedics in her state-of-the-art Puerto Madero office. ... operate phase I to phase IV clinical studies in ...
(Date:5/26/2015)... Innovacyn, a leader in developing ... and animal health industries, announced today the recipients ... Agriculture College Scholarship Award. The scholarship was open ... passionate commitment to the agriculture industry through academic ... Alexis Pedrow from Anderson County Jr/Sr High School ...
Breaking Biology Technology:RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 2Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 3
... a lot of excitement a few years ago following ... could be used to build nanoparticles of a given ... remained out of reach. An international team of researchers ... and Professor Friedrich Simmel of the Technische Universitaet Muenchen ...
... 2012 The Foundation of UMDNJ, an affiliate of ... biomarkers grant through the Bill & Melinda Gates Foundation,s ... seeks to overcome persistent bottlenecks in creating new tools ... With the grant, Dr. David Alland, ...
... United Arab Emirates   is the First Country in ... Allergy Sufferers - Nycomed, a Takeda company, ... in the United Arab Emirates for the treatment of allergic ... adults and adolescents over the age of 12.   ...
Cached Biology Technology:Nano spiral staircases modify light 2Foundation of UMDNJ Receives Grand Challenges Tuberculosis Biomarkers Grant 2Foundation of UMDNJ Receives Grand Challenges Tuberculosis Biomarkers Grant 3Nycomed, a Takeda Company, Launches Omnaris® Nasal Spray in the UAE for the Treatment of Allergic Rhinitis 2Nycomed, a Takeda Company, Launches Omnaris® Nasal Spray in the UAE for the Treatment of Allergic Rhinitis 3Nycomed, a Takeda Company, Launches Omnaris® Nasal Spray in the UAE for the Treatment of Allergic Rhinitis 4
(Date:5/22/2015)... 22, 2015 According to a ... (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), by ... Utilities, Consumer and Home) - Global Forecast to 2020", ... $2.77 Billion in 2015 to $6.19 Billion by 2020, ... 79 market data Tables and   43 Figures spread ...
(Date:5/19/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
(Date:5/14/2015)... NEW YORK , May 14, 2015 ... specializing in identity verification and online remote ... Instructure, a software-as-a-service (SaaS) company and creator ... Shared customers of the two companies will ... Proctortrack in Canvas. As a ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... University of Minnesotas Stem Cell Institute have described how ... how human embryonic stem cells differentiate. The research appears ... Medicine. Researchers know very little about how human ... cells self renewal capacity and pluripotency, and their regulation, ...
... SAFsolution Product Family Simplifies the Addition of ... Security to Thin-Client Identity Management., AUSTIN, Texas, ... SAFsolution(R) Enterprise Citrix Web Authenticator, the latest,addition to ... Enterprise Citrix Web Authenticator takes the,standard Citrix(R) web ...
... they have discovered a previously unknown population of Iberian ... endangered cat species, said World Wildlife Fund today. ... Luis Suarez, head of WWFs Species Program in Spain. ... Iberian lynx from imminent extinction. It appears that ...
Cached Biology News:IdentiPHI Introduces Biometric Authentication Solution for Citrix Web Interface Environments 2IdentiPHI Introduces Biometric Authentication Solution for Citrix Web Interface Environments 3
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
... TAMRA isomers are predominantly used for labeling ... for labeling peptides and nucleotides because they ... is often required in the conjugation processes. ... for labeling peptides and proteins. 6-TAMRA is ...
anti-Lactate Dehydrogenase...
Mouse monoclonal [6E10] to LAP2 ( Abpromise for all tested applications). entrezGeneID: 7112 SwissProtID: P42166...
Biology Products: